Concord Repatriation General Hospital-ko ikertzaileekin lankidetzan egindako argitalpenak (2)

2022

  1. Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer

    Clinical Cancer Research, Vol. 28, Núm. 7, pp. 1383-1390

2020

  1. Outcomes in clinically relevant patient subgroups from the EMBRACA study: Talazoparib vs physician's choice standard-of-care chemotherapy

    JNCI Cancer Spectrum, Vol. 4, Núm. 1